Arca
Skip to content
Tools
Tools

ADRB3: Beta-3 adrenergic receptor

G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively.

  • Drugs that act on it: 7
  • Approved: 2
  • In phases 1 to 3: 5
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on ADRB3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7

Approved2

  • Mirabegron
  • Vibegron

Phase 32

  • Amibegron
  • Ritobegron

Phase 23

  • LY377604
  • Rafabegron
  • Solabegron

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Kissei Pharmaceutical Co., Ltd.114%
    • Velicept Therapeutics, Inc.114%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Beta-3 adrenergic receptor agonist.
    MirabegronApprovedAPGDISmall moleculeAgonist33
    VibegronApprovedSumitomo PharmaSmall moleculeAgonist4
    AmibegronPhase 3SanofiSmall moleculeAgonist0
    RitobegronPhase 3Kissei Pharmaceutical Co., Ltd.Small moleculeAgonist0
    LY377604Phase 2Eli LillySmall moleculeAgonist0
    RafabegronPhase 2—Small moleculeAgonist0
    SolabegronPhase 2Velicept Therapeutics, Inc.Small moleculeAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
    Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPHMirabegronPhase 4RecruitingUniversity of California, San FranciscoSep 18, 2026
    Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive BladderMirabegron—RecruitingBagcilar Training and Research HospitalAug 19, 2026
    Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled StudyMirabegronPhase 4Not yet recruitingUniversidade do PortoJul 17, 2026
    Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson DiseaseMirabegronPhase 4Not yet recruitingCorporal Michael J. Crescenz VA Medical CenterJun 4, 2026
    Beta-3 Enhanced Autonomic Therapy for POTSMirabegronPhase 2Not yet recruitingCedars-Sinai Medical CenterMay 13, 2026
    Using Mirabegron to Control Arrhythmia-1MirabegronPhase 2Not yet recruitingCedars-Sinai Medical CenterMay 5, 2026
    Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in ChildrenMirabegron, VibegronPhase 3Active, not recruitingMenoufia UniversityFeb 9, 2026
    Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionMirabegronPhase 4RecruitingTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationDec 30, 2025
    Vibegron for ENergy Thinking and Resilience in AgingVibegronPhase 3RecruitingWake Forest University Health SciencesMay 23, 2025
    Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary IncontinenceVibegronPhase 4Active, not recruitingWomen and Infants Hospital of Rhode IslandApr 10, 2023
    Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICVibegronPhase 2 / Phase 3RecruitingUrovant Sciences GmbHAug 8, 2022

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Hypertensive disorder
    0.61
    Asthma
    0.60
    Congestive heart failure
    0.59
    Sudden cardiac arrest
    0.59
    Pain
    0.58
    Sepsis
    0.58
    Cardiovascular disorder
    0.58
    Hypotensive disorder
    0.57

    Genes and related targets

    Complexes and families that share a gene with this target
    Genes
    ADRB3

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL246, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P13945, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.